Computational evaluation of chromone–tetrazole hybrids as noncovalent inhibitors of SARS-CoV-2 Mpro
PLOS One · 11.11.2026 · 21 (11) · e0362385
DOI: 10.1371/journal.pone.0362385 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.11.2026. Verfasst von Oussama Khibech und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Mohammed Premier, Faculty of Science, Laboratory of Applied Chemistry and Environment (LCAE), Oujda, Morocco. Hauptthemen laut MEDLINE: Tetrazoles, Chromones, SARS-CoV-2, Antiviral Agents. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Emerging SARS-CoV-2 variants continue to demand orally tractable, non-covalent inhibitors of the conserved main protease (M pro ). Here, chromone-phenyl-tetrazole hybrids were prioritized using a multiscale computational strategy that connects drug-likeness, binding stability, free-energy ranking, conformational behavior, and quantum-level electronic features. The series showed favorable oral drug-like profiles and low-to-moderate predicted acute toxicity. Among the stable M pro complexes, M2 displayed the strongest computed affinity (MM/GBSA ΔG bind = −38.8 kcal·mol ⁻ ¹), driven mainly by dispersion with limited desolvation cost, whereas M4 showed the most direct catalytic-dyad engagement through His41/Cys145-supported anchoring. DFT analysis rationalized these complementary profiles: M2 and M4 exhibited narrower HOMO-LUMO gaps (4.00 eV) and higher electronic softness, while ELF/NCI maps revealed heteroatom-centered electron reservoirs and weak intramolecular preorganization. The derived pharmacophore consists of a planar chromone π-platform bearing a carbonyl/phenolic acceptor-donor edge, a para-phenyl spacer for conjugation and hydrophobic occupancy, and a methoxy-tetrazole polar/π-rich head for Glu166/Phe140/His163 anchoring. Overall, M2 and M4 emerge as complementary lead chemotypes for experimental validation and structure-guided optimization against M pro .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Mohammed Premier, Faculty of Science, Laboratory of Applied Chemistry and Environment (LCAE), Oujda, Morocco.
- Euro-Mediterranean University of Fes, UEMF, Fez, Morocco.
- BIOPI-BioEcoAgro Joint Research Unit 1158, INRAE, University of Picardie Jules Verne, Amiens, France.
- Department of Chemistry, An-Najah National University, Nablus, Palestine.
ORCID-Profile: Shehdeh Jodeh
Zitieren
APA
Khibech, O., Kadda, S., Hammouti, Y., Abadi, S., Jodeh, S., Hammouti, B., & Challioui, A. (2026). Computational evaluation of chromone–tetrazole hybrids as noncovalent inhibitors of SARS-CoV-2 Mpro. PLOS One, 21(11), e0362385. https://doi.org/10.1371/journal.pone.0362385
Vancouver
Khibech O, Kadda S, Hammouti Y, Abadi S, Jodeh S, Hammouti B, et al. Computational evaluation of chromone–tetrazole hybrids as noncovalent inhibitors of SARS-CoV-2 Mpro. PLOS One. 2026;21(11):e0362385. doi:10.1371/journal.pone.0362385
BibTeX
@article{Khibech2026,
author = {Khibech, Oussama and Kadda, Salma and Hammouti, Yousra and Abadi, Said and Jodeh, Shehdeh and Hammouti, Belkheir and Challioui, Allal},
title = {Computational evaluation of chromone–tetrazole hybrids as noncovalent inhibitors of SARS-CoV-2 Mpro},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0362385},
doi = {10.1371/journal.pone.0362385}
}
EUVIMED